P1/2, N=725, Active, not recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Trial primary completion date: Dec 2025 --> Jul 2026

Initial systemic therapy with doxorubicin achieved stable disease at three months. Based on the genomic findings identified following comprehensive genomic profiling, the patient was subsequently enrolled in the DESTINY-PanTumor02 clinical trial and transitioned to treatment with trastuzumab deruxtecan targeting the human epidermal growth factor receptor 2 (HER2) alteration...It illustrates the marked radiologic and clinicopathologic heterogeneity of IMT and emphasizes the importance of comprehensive histopathologic and molecular evaluation to guide management in aggressive disease variants. Close collaboration across cross-disciplinary diagnostic specialties is essential for the assessment and treatment of rare, multi-organ conditions.

However, with the development of resistance, the tumor microenvironment shifted to an immunosuppressive state, characterized by reactivation of transforming growth factor-beta signaling and upregulation of programmed cell death protein-1 (PD-1). These findings provide novel insights into mechanisms underlying T-DXd resistance and highlight potential therapeutic targets for overcoming T-DXd resistance in GC.

In patients with BCBM, T-DXd-associated ILD/pneumonitis occurred in 10% of patient and frequently necessitated treatment modification. Although no fatal ILD was observed, the high discontinuation rate underscored the imperative for vigilant monitoring and protocol-guided management to mitigate pulmonary toxicity while preserving intracranial efficacy.

P1, N=48, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University

P3, N=540, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Approximately 40 % of young women with luminal HER2-negative breast cancers have HER2-low or ultralow disease. These findings highlight the importance of accurately assessing HER2 expression in YWBC to identify candidates for emerging HER2-targeted therapies such as trastuzumab deruxtecan.

P=N/A, N=20, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P=N/A, N=30, Recruiting, Dalian Medical University Second Affiliated Hospital; Dalian Medical University Second Affiliated Hospital

P=N/A, N=50, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

P=N/A, N=200, Not yet recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University